Galectin Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 41.07 million compared to USD 38.78 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to USD 0.65 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.365 USD | -0.15% | -2.32% | +103.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.01% | 209M | |
+25.71% | 48.09B | |
+46.90% | 40.62B | |
-3.44% | 40.43B | |
-6.20% | 28.36B | |
+9.14% | 24.89B | |
-20.35% | 19.01B | |
+28.20% | 12.09B | |
+0.43% | 11.88B | |
-1.17% | 11.8B |
- Stock Market
- Equities
- GALT Stock
- News Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023